Grazia Crescimanno
Overview
Explore the profile of Grazia Crescimanno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crescimanno G, Lupica A, Tomasello V, Di Stefano V, Brighina F, Marrone O
Sci Rep
. 2025 Feb;
15(1):6478.
PMID: 39987313
This study aimed to examine feasibility of inspiratory muscle strength tests, such as maximal inspiratory pressure (MIP) and sniff nasal inspiratory pressure (SNIP) in adult patients affected by spinal muscular...
2.
Crescimanno G, Lupica A, Tommasello V, Di Stefano V, Brighina F, Marrone O
J Sleep Res
. 2024 Apr;
33(6):e14222.
PMID: 38654474
Sleep-disordered breathing is common among children with spinal muscular atrophy, but has been hardly studied among adult subjects. Little is known about sleep quality in spinal muscular atrophy. The aims...
3.
Marci M, Crescimanno G, Vaccaro P
G Ital Cardiol (Rome)
. 2024 Mar;
25(4):294.
PMID: 38526366
No abstract available.
4.
Di Stefano V, Iacono S, Militello M, Leone O, Rispoli M, Ferri L, et al.
Neurol Sci
. 2024 Feb;
45(7):3481-3494.
PMID: 38383750
Background: Myasthenia gravis (MG) is an autoimmune disorder with fluctuating weakness that causes significant disability and morbidity. Comorbidities may influence the course of MG, particularly in specific subgroups. The aim...
5.
Toscano A, Musumeci O, Sacchini M, Ravaglia S, Siciliano G, Fiumara A, et al.
Orphanet J Rare Dis
. 2023 Oct;
18(1):338.
PMID: 37891668
Background: The Italian Medicines Agency (AIFA) demands precise information on benefit/risk profile of home-based enzyme replacement therapy (ERT) for the treatment of patients with Pompe disease and Mucopolysaccharidosis type I...
6.
Crescimanno G, Lupica A, Tomasello V, Di Stefano V, Brighina F, Marrone O
Sleep Med
. 2023 Oct;
112:149-150.
PMID: 37865031
No abstract available.
7.
Crescimanno G, Greco F, Bertini M, Maltese G, Marrone O
J Neuromuscul Dis
. 2023 May;
10(5):955-962.
PMID: 37212070
Background: In Duchenne muscular dystrophy (DMD), dysphagia is a common but often overlooked symptom, which may affect quality of life (QoL). Its possible causes are progressive deterioration of muscle groups...
8.
Racca F, Sansone V, Ricci F, Filosto M, Pedroni S, Mazzone E, et al.
Acta Myol
. 2023 Feb;
41(4):135-177.
PMID: 36793651
Acute hospitalisation may be required to support patients with Neuromuscular disorders (NMDs) mainly experiencing respiratory complications, swallowing difficulties, heart failure, urgent surgical procedures. As NMDs may need specific treatments, they...
9.
Crescimanno G, Greco F, Bertini M, Marrone O
Heart Lung
. 2022 Aug;
56:161-166.
PMID: 35930914
Background: Cardiovascular events commonly cause death in amyotrophic lateral sclerosis (ALS) even in patients treated by noninvasive ventilation (NIV). Objectives: to evaluate autonomic function with the assessment of heart rate...
10.
Ravaglia S, De Giuseppe R, Carlucci A, Jehne S, Crescimanno G, Ahmad L, et al.
Front Cell Dev Biol
. 2022 Mar;
10:793566.
PMID: 35252175
Late-onset Pompe disease (LOPD) is an autosomal-recessive metabolic myopathy caused by deficiency of the lysosomal enzyme Acid Alpha-Glucosidase (GAA), leading to glycogen accumulation in proximal and axial muscles, and in...